Skip to Main Content

Biopharma can find plenty to celebrate — and a few things to despair over — in the new Republican plan to rewrite the tax code.

The long awaited “Tax Cuts and Jobs Act,” unveiled as a House bill on Thursday, will likely still be revised significantly. But so far, here are the seven provisions with the biggest implications for the drug industry:

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!